Impact Biomedical stock soars after merger deal with Dr Ashleys

Published 23/06/2025, 17:08
© Reuters.

Investing.com -- Impact BioMedical Inc. (NYSE American:IBO) stock soared 385% following the announcement of a strategic merger with Hong Kong-based pharmaceutical company Dr Ashleys Limited.

The companies signed a merger and share exchange agreement on June 21, 2025, that will result in a reverse merger creating a combined entity to be traded on the NYSE American under the name "Dr Ashleys Limited," according to a joint statement from the firms.

Under the terms of the agreement, Impact BioMedical will become a wholly-owned subsidiary of the newly formed public company, which will be operated by Dr Ashleys’ management team. The transaction has received unanimous approval from both companies’ boards of directors, though it remains subject to Impact BioMedical shareholder approval and regulatory clearances.

Dr. Kanans Visvanats, Director of Dr Ashleys Limited, described the merger as "a significant milestone" that would accelerate the development of new therapies by integrating Impact BioMedical’s intellectual property portfolio into Dr Ashleys’ research and development efforts.

Frank D. Heuszel, CEO of Impact BioMedical, expressed enthusiasm about the deal, noting that Dr Ashleys’ "global reach and financial strength will provide the resources and infrastructure needed to bring our innovations to market."

The transaction represents a strategic move highlighting the importance of collaboration in the biomedical industry, with Dr Ashleys’ global presence and financial capabilities potentially enhancing the market prospects for Impact BioMedical’s patents.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.